Sidharth Kerkar
Founder & Chief Executive Officer AllerGene AI
Sid is a Pharma/Biotech leader and cell therapy innovator behind the discovery of MAGE-A as a pan-cancer target and next-generation T cell engineering with IL-12, now pioneering in vivo gene engineering to treat and prevent life-threatening allergies and anaphylaxis. Previous experience includes roles at Bristol Myers Squibb, Boehringer-Ingelheim Pharmaceutical, Eli Lilly & Company, Exuma Biotech
